Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1832 results
November 2015
-
Media ReleaseNovartis' heart failure medicine Entresto(TM) receives EU approvalDecision brings hope of longer and better life with fewer hospitalizations for millions of Europeans with symptomatic chronic heart failure with reduced ejection fraction Entresto is the…
-
Media ReleaseNovartis receives two landmark European approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritisCosentyx is the first and only IL-17A inhibitor from a new class of medicines shown to treat two of the most common inflammatory joint conditions in Europe[1] Cosentyx shows rapid and…
-
Media ReleaseNovartis Pharmaceuticals Corporation finalizes settlement agreement resolving civil suit filed by the U.S. Attorney's Office for the Southern District of New YorkNovartis Pharmaceuticals Corporation (NPC) has agreed to certain provisions relating to specialty pharmacies as part of an addendum to its existing corporate integrity agreement (CIA), which will…
-
Media ReleaseRegulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDASandoz continues to advance its biosimilars program: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA Sandoz demonstrates commitment to oncology by seeking…
-
Media ReleaseFLAME study shows superiority of Novartis' Ultibro® Breezhaler® over Seretide® in reducing COPD exacerbationsUltibro® Breezhaler® met primary endpoint and demonstrated superiority to Seretide® in reducing COPD exacerbations during 52 weeks of treatment First large-scale study to confirm Ultibro…
-
Media ReleaseAlcon introduces Contoura Vision as first personalized LASIK procedure at American Academy of Ophthalmology Annual MeetingNearly 65% of eyes treated with personalized topography-guided LASIK experienced 20/16 vision or better[1] in clinical study Alcon is the first refractive laser manufacturer to receive FDA…
-
Media ReleaseNovartis presents new two year data for Cosentyx® showing no progression in joint damage in 84% of psoriatic arthritis patientsNew x-ray assessment data, from a sub-study, showed no progression of joint structural damage in the majority of patients with psoriatic arthritis over two years[1] Psoriatic arthritis patients on…
-
Media ReleaseNew two year data for Novartis' Cosentyx® show sustained response and no progression in spinal damage as shown by x-ray in up to 80% of patients with ankylosing spondylitisA sub-study showed up to 80% of ankylosing spondylitis (AS) patients treated with Cosentyx had no radiographic progression in the spine over two years[1] Cosentyx demonstrated a sustained…
-
Giraffes have high blood pressure. Why don’t they drop dead?
A certain leggy resident of the African grasslands is arousing a lot of interest among evolutionary biologists. They believe that study of giraffes' unique features could lead the way to advances in human health.
-
Media ReleaseNovartis nominating Elizabeth Doherty and Ton Buechner to the Board of DirectorsNominees for election by shareholders at Annual General Meeting (AGM) in February 2016 Basel, November 4, 2015 - The Novartis Board of Directors announced today, that it is nominating Ms.…
October 2015
-
Media ReleaseNovartis Foundation and partners launch new hypertension program in GhanaCommunity-based Hypertension Improvement Project (ComHIP) is an innovative healthcare model designed to improve hypertension management and control Screening and treatment is shifted to the…
-
Stepping toward regenerative medicine for diabetes
Discovery points toward treatment options beyond insulin injections
Pagination
- ‹ Previous page
- 1
- …
- 134
- 135
- 136
- 137
- 138
- 139
- 140
- …
- 153
- › Next page